Roth Capital Affirms Neuralstem (CUR) at 'Buy'; Says Rest of 2016 Will be Uneventful
Tweet Send to a Friend
Roth Capital affirms Neuralstem (Nasdaq: CUR) at Buy with a price target of $1.20 following Q3 results report today.The firm ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
